Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and Neulasta® in Healthy Adult Subjects

Trial Profile

A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and Neulasta® in Healthy Adult Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Cancer
  • Focus Pharmacodynamics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 09 Oct 2018 According to a Fresenius Kabi media release, primary endpoint (to Assess the Immunogenicity of MSB11455 Compared to Neulasta) has been met.
    • 07 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top